Eight-year outcomes of the Childhood Asthma Prevention Study

• Published in: Journal of allergy and clinical immunology Vol. 126; no. 2; pp. 388 - 389.e3
• Main Authors: Toelle, Brett G., PhD, Ng, Kitty K.W., MPH(Hons), Crisafulli, Daniele, BSc, Belousova, Elena G., MSc(AppMath), Almqvist, Catarina, PhD, Webb, Karen, PhD, Tovey, Euan R., PhD, Kemp, Andrew S., PhD, Mellis, Craig M., MD, Leeder, Stephen R., PhD, Marks, Guy B., PhD
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.08.2010; Elsevier Limited
• Subjects: Age; Age Factors; Allergy and Immunology; Animals; Asthma; Asthma - epidemiology; Asthma - etiology; Asthma - prevention & control; Child; Child, Preschool; Children & youth; Clinical outcomes; Dietary Fats, Unsaturated - administration & dosage; Dietary Fats, Unsaturated - pharmacokinetics; Dust; Fatty Acids, Omega-3 - administration & dosage; Fatty Acids, Omega-3 - pharmacokinetics; Fatty Acids, Omega-6 - administration & dosage; Fatty Acids, Omega-6 - pharmacokinetics; Female; Follow-Up Studies; Humans; Intervention; Male; Medicin och hälsovetenskap; Nitric oxide; Plasma; Prevalence; Pyroglyphidae; Risk Factors; Statistical methods
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2010.04.031

To the Editor: The Childhood Asthma Prevention Study is a randomized controlled trial to test the effectiveness of house dust mite (HDM) avoidance and dietary fatty acid modification during the first 5 years of life as strategies for the primary prevention of asthma and allergy in high-risk children. Â HDM intervention Diet intervention Outcome Active (%) Control (%) Absolute risk reduction[low *] (95% CI) Active (%) Control (%) Absolute risk reduction[low *] (95% CI) Atopy 43.9 46.1 2.2 (-7.5 to 12.0) 45.1 45.0 -0.2 (-9.9 to 9.6) HDM allergy 33.2 37.9 4.7 (-4.6 to 14.1) 38.2 32.8 -5.4 (-14.8 to 3.9) Wheeze 29.6 25.7 -3.9 (-12.2 to 4.4) 31.7 23.2 -8.6 (-16.8 to -0.4) AHR 18.5 18.4 0.1 (-8.1 to 8.0) 18.0 19.0 1.0 (-7.1 to 9.0) Asthma 23.2 21.7 -1.4 (-9.2 to 6.3) 24.8 20.0 -4.8 (-12.5 to 2.9) Poor asthma control 8.6 10.9 2.2 (-3.2 to 7.7) 10.4 9.1 -1.3 (-6.8 to 4.1) Eczema 14.4 15.0 0.6 (-6.1 to 7.3) 15.3 14.2 -1.1 (-7.8 to 5.6) Rhinitis 32.3 27.8 -4.5 (-12.9 to 4.0) 30.4 29.6 -0.9 (-9.4 to 7.6) Serum total IgE >1000 IU 9.7 8.6 -1.1 (-7.5 to 5.3) 8.5 9.9 1.5 (-4.9 to 7.8) Specific anti-HDM IgE positive 43.0 42.4 -0.7 (-11.3 to 9.9) 44.8 40.4 -4.5 (-15.0 to 6.1) FeNO >15 ppb 12.2 11.9 -0.3 (-6.7 to 6.1) 13.4 10.8 -2.6 (-9.0 to 3.8) Table I Effect of the interventions on clinical outcomes assessed at 8 years of age AHR, Airway hyperresponsiveness; FeNO, fraction of exhaled nitric oxide.